Assay-kits

SensoLyte® Anti-MOG(35-55) IgG Quantitative ELISA Kit (mouse/rat) Colorimetric - 1 kit

$554.00
Check your price
  • Cat.Number : AS-54465
  • Availability :
    In stock
  • Shipping conditions : Ice delivery fees must be applied

Alternative choices

Quantity

MOG peptide fragment (35-55) [Cat# AS-60130] induces autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination. Autoantibody response to MOG (35-55) is present in multiple sclerosis (MS) patients and MOG (35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice.
The SensoLyte® Anti-MOG (35-55) IgG Quantitative ELISA Kit (mouse/rat) provides a convenient, quantitative assay for detecting anti-MOG (35-55) IgG. This colorimetric assay, useful for determining the amount of anti-MOG (35-55) IgG present, can help provide information on the role anti-MOG (35-55) IgG plays in the development of EAE, an in vivo animal model for MS pathogenesis. The assays are performed in a convenient 96-well (strips format).

Specifications

Packaging
Kits components
  • Component A: MOG (35-55) coated and BSA blocked 8-well strips: 12 strips Component B: Mouse anti-MOG (35-55) IgG standard: 100 µl (20 µg/ml) Component C: 1X Sample Dilution Buffer: 30 ml Component D: 10X Wash Buffer: 50 ml Component E: TMB color substrate solution: 10 ml Component F: Stop Solution: 10 ml Component G: Secondary antibody, Goat anti-Mouse IgG-HRP: 30 µl Component H: Secondary antibody, Goat anti-Rat IgG-HRP: 30 µl Component J: Rat anti-MOG (35-55) IgG standard: 100 µl (20 µg/ml)
Chemistry
UniProt number
  • Q61885, Q63345
Storage & stability
Storage Conditions
  • Store all kit components at 2-8°C for up to 6 months.
Activity
Application
Biomarker Target
Detection Method
Detection Limit
  • 1 ng/ml
Research Area
Sub-category Research Area
Usage
  • Research use
Codes
Code Nacres
  • NA.32

You may also be interested in the following product(s)

Citations

Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions

PLoS ONE . 2008 Oct 02 ; 3 e3321 | DOI : 10.1371/journal.pone.0003321

  • E. Hatterer
  • et al